VYNE Therapeutics (NASDAQ:VYNE) Shares Down 1.4% – Time to Sell?
by Tristan Rich · The Markets DailyVYNE Therapeutics Inc. (NASDAQ:VYNE – Get Free Report) shares traded down 1.4% during mid-day trading on Friday . The company traded as low as $0.6301 and last traded at $0.6561. 50,971 shares traded hands during mid-day trading, a decline of 64% from the average session volume of 142,873 shares. The stock had previously closed at $0.6651.
Wall Street Analyst Weigh In
Separately, Weiss Ratings restated a “sell (d-)” rating on shares of VYNE Therapeutics in a research report on Monday, May 4th. Three investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Reduce”.
Check Out Our Latest Stock Analysis on VYNE Therapeutics
VYNE Therapeutics Stock Performance
The company’s fifty day simple moving average is $0.64 and its two-hundred day simple moving average is $0.57. The stock has a market capitalization of $21.88 million, a PE ratio of -1.73 and a beta of 2.00.
VYNE Therapeutics (NASDAQ:VYNE – Get Free Report) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.10. VYNE Therapeutics had a negative net margin of 4,726.21% and a negative return on equity of 70.42%. The business had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.20 million. Sell-side analysts forecast that VYNE Therapeutics Inc. will post -1.1 EPS for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the stock. XTX Topco Ltd acquired a new position in shares of VYNE Therapeutics in the 4th quarter valued at approximately $46,000. Rangeley Capital LLC raised its stake in VYNE Therapeutics by 18.1% during the first quarter. Rangeley Capital LLC now owns 118,064 shares of the company’s stock valued at $71,000 after buying an additional 18,064 shares in the last quarter. Two Sigma Investments LP acquired a new position in shares of VYNE Therapeutics in the 3rd quarter worth approximately $74,000. Geode Capital Management LLC increased its holdings in shares of VYNE Therapeutics by 64.2% in the 4th quarter. Geode Capital Management LLC now owns 225,152 shares of the company’s stock valued at $131,000 after acquiring an additional 88,030 shares during the last quarter. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of VYNE Therapeutics during the 4th quarter valued at approximately $147,000. Institutional investors and hedge funds own 83.78% of the company’s stock.
VYNE Therapeutics Company Profile
VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.
The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.